Scientists hunt for biomarkers of PARP inhibitor resistance in BRCA breast cancer
NCT ID NCT05378204
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study is collecting tumor and blood samples from 120 people with advanced, HER2-negative breast cancer who have a BRCA1/2 mutation. Researchers want to see if certain DNA repair proteins (POLQ, Shieldin complex, 53BP1) can predict whether a tumor will resist PARP inhibitor drugs like olaparib or talazoparib. The goal is to better understand resistance and potentially guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CENTRE ARMORICAIN DE RADIOTHERAPIE, IMAGERIE MEDICALE ET ONCOLOGIE - Hôpital privé des Côtes d'Armor
NOT_YET_RECRUITINGPlérin, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de LIMOGES
RECRUITINGLimoges, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Nimes
RECRUITINGNîmes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Eugene Marquis
WITHDRAWNRennes, France
-
Centre Francois Baclesse
RECRUITINGCaen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Georges Francois Leclerc
WITHDRAWNDijon, France
-
Centre Hospitalier Départemental Vendée
RECRUITINGLa Roche-sur-Yon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Leon Berard
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Oscar Lambret
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre de Cancerologie Du Grand Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chru de Tours
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu Saint Etienne
RECRUITINGSaint-Etienne, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chu de Poitiers
RECRUITINGPoitiers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Pitie Salpetriere
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Tenon
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
INSTITUT CURIE - Site de Paris
WITHDRAWNParis, France
-
INSTITUT DE CANCEROLOGIE DE L'OUEST St-Herblain
RECRUITINGSaint-Herblain, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IUCT-O
RECRUITINGToulouse, France
Contact Email: •••••@•••••
-
Institut Bergonie
RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Regional Du Cancer de Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancerologie de Lorraine
RECRUITINGVandœuvre-lès-Nancy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which patients are likely to resist PARP inhibitors, allowing more personalized treatment choices.
What could go wrong
This is an observational biomarker study, not a treatment trial. It may not lead to immediate clinical changes, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.